XORTX Depreciation And Amortization vs Total Operating Expenses Analysis

XRTX Stock  USD 1.21  0.03  2.54%   
XORTX Therapeutics financial indicator trend analysis is more than just analyzing XORTX Therapeutics current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether XORTX Therapeutics is a good investment. Please check the relationship between XORTX Therapeutics Depreciation And Amortization and its Total Operating Expenses accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XORTX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.

Depreciation And Amortization vs Total Operating Expenses

Depreciation And Amortization vs Total Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of XORTX Therapeutics Depreciation And Amortization account and Total Operating Expenses. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between XORTX Therapeutics' Depreciation And Amortization and Total Operating Expenses is 0.5. Overlapping area represents the amount of variation of Depreciation And Amortization that can explain the historical movement of Total Operating Expenses in the same time period over historical financial statements of XORTX Therapeutics, assuming nothing else is changed. The correlation between historical values of XORTX Therapeutics' Depreciation And Amortization and Total Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation And Amortization of XORTX Therapeutics are associated (or correlated) with its Total Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Operating Expenses has no effect on the direction of Depreciation And Amortization i.e., XORTX Therapeutics' Depreciation And Amortization and Total Operating Expenses go up and down completely randomly.

Correlation Coefficient

0.5
Relationship DirectionPositive 
Relationship StrengthWeak

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.
Most indicators from XORTX Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into XORTX Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XORTX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.Selling General Administrative is likely to drop to about 1 M in 2024. Issuance Of Capital Stock is expected to grow at the current pace this year
 2021 2022 2023 2024 (projected)
Reconciled Depreciation17.9K55.5K139.7K146.7K
Research Development669.1K6.5M3.2M1.7M

XORTX Therapeutics fundamental ratios Correlations

0.730.820.98-0.27-0.99-0.580.530.990.90.990.760.63-0.250.891.0-0.35-0.43-0.740.910.61-0.620.560.95-0.150.97
0.730.940.76-0.41-0.72-0.10.120.720.470.720.170.15-0.350.560.74-0.09-0.15-0.280.580.42-0.380.270.60.160.82
0.820.940.8-0.51-0.81-0.240.440.810.60.810.350.24-0.440.770.83-0.09-0.17-0.340.620.54-0.50.370.740.190.84
0.980.760.8-0.23-0.98-0.550.390.980.880.980.710.61-0.190.80.98-0.38-0.45-0.750.920.58-0.580.560.9-0.170.99
-0.27-0.41-0.51-0.230.20.45-0.33-0.21-0.31-0.21-0.14-0.35-0.19-0.31-0.260.210.280.25-0.31-0.570.56-0.52-0.120.19-0.29
-0.99-0.72-0.81-0.980.20.51-0.51-1.0-0.88-1.0-0.73-0.570.28-0.88-0.990.310.380.7-0.89-0.540.54-0.48-0.960.12-0.97
-0.58-0.1-0.24-0.550.450.51-0.49-0.51-0.76-0.51-0.82-0.98-0.44-0.49-0.550.70.770.86-0.78-0.790.84-0.9-0.450.71-0.53
0.530.120.440.39-0.33-0.51-0.490.510.550.510.670.38-0.420.830.52-0.15-0.23-0.30.330.57-0.570.440.660.110.34
0.990.720.810.98-0.21-1.0-0.510.510.881.00.730.57-0.290.890.99-0.3-0.37-0.70.880.53-0.540.480.96-0.110.97
0.90.470.60.88-0.31-0.88-0.760.550.880.880.880.790.050.80.88-0.4-0.48-0.870.920.61-0.630.70.84-0.340.85
0.990.720.810.98-0.21-1.0-0.510.511.00.880.730.57-0.290.890.99-0.3-0.37-0.70.880.53-0.540.480.96-0.110.97
0.760.170.350.71-0.14-0.73-0.820.670.730.880.730.820.00.740.74-0.59-0.65-0.780.780.7-0.720.770.75-0.350.65
0.630.150.240.61-0.35-0.57-0.980.380.570.790.570.820.480.470.6-0.7-0.77-0.910.850.73-0.780.850.48-0.780.6
-0.25-0.35-0.44-0.19-0.190.28-0.44-0.42-0.290.05-0.290.00.48-0.48-0.28-0.3-0.3-0.370.170.02-0.080.29-0.44-0.84-0.15
0.890.560.770.8-0.31-0.88-0.490.830.890.80.890.740.47-0.480.89-0.18-0.27-0.540.680.58-0.580.460.950.080.78
1.00.740.830.98-0.26-0.99-0.550.520.990.880.990.740.6-0.280.89-0.35-0.42-0.710.890.61-0.610.540.95-0.130.97
-0.35-0.09-0.09-0.380.210.310.7-0.15-0.3-0.4-0.3-0.59-0.7-0.3-0.18-0.350.990.49-0.53-0.730.75-0.77-0.210.53-0.36
-0.43-0.15-0.17-0.450.280.380.77-0.23-0.37-0.48-0.37-0.65-0.77-0.3-0.27-0.420.990.58-0.61-0.80.83-0.84-0.280.56-0.43
-0.74-0.28-0.34-0.750.250.70.86-0.3-0.7-0.87-0.7-0.78-0.91-0.37-0.54-0.710.490.58-0.91-0.560.61-0.71-0.610.65-0.73
0.910.580.620.92-0.31-0.89-0.780.330.880.920.880.780.850.170.680.89-0.53-0.61-0.910.65-0.680.70.77-0.530.92
0.610.420.540.58-0.57-0.54-0.790.570.530.610.530.70.730.020.580.61-0.73-0.8-0.560.65-1.00.930.47-0.310.58
-0.62-0.38-0.5-0.580.560.540.84-0.57-0.54-0.63-0.54-0.72-0.78-0.08-0.58-0.610.750.830.61-0.68-1.0-0.94-0.470.39-0.58
0.560.270.370.56-0.52-0.48-0.90.440.480.70.480.770.850.290.460.54-0.77-0.84-0.710.70.93-0.940.39-0.480.54
0.950.60.740.9-0.12-0.96-0.450.660.960.840.960.750.48-0.440.950.95-0.21-0.28-0.610.770.47-0.470.390.020.87
-0.150.160.19-0.170.190.120.710.11-0.11-0.34-0.11-0.35-0.78-0.840.08-0.130.530.560.65-0.53-0.310.39-0.480.02-0.21
0.970.820.840.99-0.29-0.97-0.530.340.970.850.970.650.6-0.150.780.97-0.36-0.43-0.730.920.58-0.580.540.87-0.21
Click cells to compare fundamentals

XORTX Therapeutics Account Relationship Matchups

XORTX Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets1.1M2.3M17.3M12.3M5.5M5.0M
Other Current Liab641.5K728.4K3.8M151.4K87.6K83.2K
Total Current Liabilities1.3M1.0M4.2M1.5M294.9K280.2K
Total Stockholder Equity(211.7K)1.3M13.1M7.0M4.6M3.1M
Property Plant And Equipment Net731.0341.00.092.5K23.9K28.8K
Net Debt(7.8K)(171.3K)(14.8M)(10.3M)(3.4M)(3.6M)
Retained Earnings(6.8M)(8.0M)(7.6M)(14.1M)(17.9M)(17.0M)
Accounts Payable607.4K305.8K324.0K1.3M195.8K186.0K
Cash58.6K171.3K14.8M10.4M3.4M3.6M
Non Current Assets Total272.7K234.3K1.5M1.5M1.4M731.9K
Cash And Short Term Investments58.6K171.3K14.8M10.4M3.4M3.6M
Net Receivables15.5K14.4K40.7K81.8K60.7K35.1K
Common Stock Shares Outstanding595.5K740.4K1.1M1.5M2.0M2.1M
Liabilities And Stockholders Equity1.1M2.3M17.3M12.3M5.5M5.0M
Other Stockholder Equity683.0K0.0(1.4M)(2.4M)5.5M5.8M
Total Liab1.3M1.0M4.2M5.4M825.9K784.6K
Total Current Assets815.2K2.1M15.8M10.9M4.1M4.2M
Short Long Term Debt Total272.5K43.3K50.8K77.4K11.5K10.9K
Intangible Assets272.4K234.3K201.0K199.4K175.3K189.0K
Net Tangible Assets(484.1K)1.0M16.5M9.2M10.6M11.1M
Net Invested Capital(160.9K)1.3M16.7M7.0M4.6M4.6M
Net Working Capital(484.5K)1.0M14.9M9.4M3.8M4.3M
Other Current Assets741.2K2.1M1.0M379.6K560.4K728.6K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.